News
EQS-Adhoc: Formycon AG plans capital increase of approx. 5% of the share capital by way of an accelerated bookbuilding procedure to finance further growth
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for
EQS-News: Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting
ABIVAX: NOTICE TO HOLDERS OF BONDS CONVERTIBLE AND/OR EXCHANGEABLE INTO NEW AND/OR EXISTING SHARES (OCEANES) WITH A NOMINAL VALUE OF EUR 24,999,975.99
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
Pfizer Inc. (NYSE: PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance(4).
The fourth-quarter 2022 earnings presentation and
Sensorion and EVEON Collaborating to Develop an Injection System for the Delivery of Gene Therapy Treatments Into the Inner Ear
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Valbiotis gibt positive Ergebnisse der klinischen Studie zur Bioverfügbarkeit und Wirkungsweise von TOTUM•854 gegen Bluthochdruck bekannt
Pflichtmitteilung:
Valbiotis (FR0013254851 - ALVAL, PEA / KMU-qualifiziert) (Paris:ALVAL), ein kommerziell ausgerichtetes Forschungs- und Entwicklungsunternehmen, das sich auf wissenschaftliche
Agilent to Announce First-Quarter Fiscal Year 2023 Financial Results Feb. 28
Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2023 after the stock market closes on Tuesday, Feb. 28. The company will host a live webcast
Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM•854 Clinical Study, Against High Blood Pressure
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, with a commercial purpose, committed to scientific
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Charles River Laboratories Acquires SAMDI Tech
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired SAMDI Tech, Inc, a leading provider of high-quality, label-free high-throughput screening (HTS)
EQS-News: Sernova Announces Advancements with its Novel Cell Pouch System(TM) to Preserve Thyroid Function Following Total Thyroidectomy
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Go365 by Humana Announces Winners of Fifth Annual National Step Challenge, Resulting in 7.1 Billion Steps Taken and One Million Meals* Donated to Feeding America®
Today, leading health and well-being company, Humana Inc. (NYSE: HUM), announced the winners** of its 2022 Go365® National Step Challenge – a health and wellness competition that focuses on
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Aurinia Announces PTAB Has Terminated Inter Partes Review
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia) announces that the Patent Trial and Appeal Board (PTAB) of the United States’ Patent and Trademark Office has terminated the Inter Partes
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Lysogene: Conversion of the Safeguard Proceedings Into Reorganization Proceedings
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces the conversion of the safeguard
Poxel Receives Orphan Drug Designation from the European Commission for PXL770 and PXL065 for Treatment of Adrenoleukodystrophy
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office (USPTO) has allowed a method of use patent application titled
Karen Moran Named President of Humana Military
Humana Military, a wholly owned subsidiary of Humana Inc. (NYSE: HUM), announced today that it has appointed healthcare industry veteran Karen Moran to Senior Vice President, President of Humana
Dexcom Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 9, 2023 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2022 financial results after market close on Thursday, February 9, 2023. Management will hold a
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system